Owkin and Sanofi Partner to Develop AI Agents for Drug Discovery
Owkin and Sanofi have expanded their multi-year K Pro collaboration to develop AI agents that enhance drug discovery and development. By integrating agentic AI systems into research workflows, the partnership aims to unlock the full value of data, improve decision-making, and accelerate the development of innovative therapies.
AI In Drug Discovery | 06/06/2026 | By News Bureau
Tempus Launches Next-Generation Lens AI Platform for Oncology Drug Development
Tempus has unveiled the next-generation Lens platform, expanding its agentic AI capabilities for oncology drug development by leveraging over a decade of longitudinal real-world data and advanced analytics to generate actionable insights for biopharma research, clinical development, and precision medicine.
AI In Drug Discovery | 01/06/2026 | By News Bureau | 105
Harbour BioMed Reports Promising Preclinical Data for AI-Driven Drug Candidate LET003
Harbour BioMed announced promising preclinical data for LET003, its first Artificial Intelligence (AI)-enabled drug candidate, highlighting potential as a next-generation obesity therapy targeting ACVR2A/2B.
AI In Drug Discovery | 18/05/2026 | By News Bureau | 249
BioMed X Launches First Research Team in France to Advance AI-Driven Antibody Design
BioMed X launches AI-focused antibody research team in France, aiming to accelerate development of next-generation biologic therapies for cancer and immune diseases.
AI In Drug Discovery | 21/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy